↓ Skip to main content

Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer

Overview of attention for article published in Journal of Cachexia, Sarcopenia and Muscle, January 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
73 tweeters

Citations

dimensions_citation
116 Dimensions

Readers on

mendeley
133 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer
Published in
Journal of Cachexia, Sarcopenia and Muscle, January 2018
DOI 10.1002/jcsm.12267
Pubmed ID
Authors

Louise E. Daly, Éadaoin B. Ní Bhuachalla, Derek G. Power, Samantha J. Cushen, Karl James, Aoife M. Ryan

Abstract

Malnutrition, weight loss, and muscle wasting are common in patients with foregut cancers (oesophagus, stomach, pancreas, liver, and bile ducts) and are associated with adverse clinical outcomes. However, little is known about the changes in body composition that occur in these patients during chemotherapy and its impacts clinical outcomes. A prospective study of adult foregut cancer patients undergoing chemotherapy between 2012 and 2016 was conducted. Computed tomography images were evaluated for cross-sectional skeletal muscle area (SMA) and adipose tissue area (ATA) at two time points [interval 118 days (IQR 92-58 days)]. Longitudinal changes in SMA and ATA were examined using paired t-tests. Sarcopenia and low muscle attenuation (MA) were defined using published cut-points. Cox proportional hazards models were used to estimate mortality hazard ratios for key predictors. A total of 225 foregut cancer patients were included (67% male, median age 66 years). At baseline, 40% were sarcopenic, 49% had low MA, and 62% had cancer cachexia. Longitudinal analysis (n = 163) revealed significant reductions in SMA [-6.1 cm2 (3.9%)/100 days, P < 0.001]. Patients treated with neoadjuvant chemotherapy experienced greater losses in SMA and skeletal muscle mass compared with patients receiving palliative chemotherapy [-6.6 cm2 (95%, confidence interval, CI: -10.2 to -3.1), P < 0.001 and -1.2 kg (95% CI: -1.8 to -0.5), P < 0.001, respectively]. Neither sarcopenia nor low MA at baseline was associated with reduced survival. A loss of SMA >6.0%/100 days (highest fourth) independently predicted overall survival in patients receiving palliative chemotherapy [hazard ratio: 2.66, (95% CI: 1.42 to 4.97), P = 0.002]. Patients with foregut cancers, particularly those treated with neoadjuvant chemotherapy, experience significant losses of muscle during chemotherapy. A high level of SMA loss is prognostic of reduced survival in patients treated with palliative chemotherapy. Multimodal interventions to stabilize or increase muscle mass and influence outcome warrant further investigation.

Twitter Demographics

The data shown below were collected from the profiles of 73 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 133 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 15%
Student > Ph. D. Student 18 14%
Researcher 15 11%
Student > Bachelor 13 10%
Other 9 7%
Other 23 17%
Unknown 35 26%
Readers by discipline Count As %
Medicine and Dentistry 49 37%
Nursing and Health Professions 11 8%
Unspecified 5 4%
Agricultural and Biological Sciences 5 4%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 19 14%
Unknown 40 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 50. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2019.
All research outputs
#652,006
of 21,337,804 outputs
Outputs from Journal of Cachexia, Sarcopenia and Muscle
#55
of 779 outputs
Outputs of similar age
#20,237
of 442,443 outputs
Outputs of similar age from Journal of Cachexia, Sarcopenia and Muscle
#2
of 8 outputs
Altmetric has tracked 21,337,804 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 779 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,443 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.